Personalis Inc (PSNL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.70B
Last updated: Nov 17, 2026 at 11:06 AM ET
Personalis Inc (PSNL) Earnings: Report Dates and Results
Personalis (PSNL) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Personalis reported EPS of -$0.32, below the -$0.25 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PSNL has an expected report date of Feb 24, 2027.
PSNL Earnings Call
The latest PSNL earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 30 quarters below that had an estimate, PSNL beat 19 and missed 11. Revenue for the quarter ended Sep 30, 2026 was $25.60M, up 76.7% from $14.49M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.32 | -$0.25 | -$0.32 - -$0.23 | -28.00% | Miss | N/A | 6 | 1 up, 0 down | Nov 4, 2026 | $25.60M |
| Jun 30, 2026 | -$0.30 | -$0.25 | N/A | -20.00% | Miss | N/A | 6 | 3 up, 2 down | Aug 4, 2026 | $22.36M |
| Mar 31, 2026 | -$0.29 | -$0.28 | -$0.32 - -$0.24 | -3.57% | Miss | N/A | 5 | 1 up, 2 down | May 7, 2026 | $15.47M |
| Dec 31, 2025 | -$0.26 | -$0.31 | -$0.31 - -$0.27 | +16.13% | Beat | N/A | 6 | 0 up, 1 down | Feb 26, 2026 | $17.34M |
| Sep 30, 2025 | -$0.24 | -$0.27 | -$0.30 - -$0.23 | +11.11% | Beat | N/A | 7 | 0 up, 7 down | Nov 4, 2025 | $14.49M |
| Jun 30, 2025 | -$0.23 | -$0.24 | -$0.27 - -$0.23 | +4.17% | Beat | N/A | 7 | 2 up, 0 down | Aug 5, 2025 | $17.20M |
| Mar 31, 2025 | -$0.18 | -$0.25 | -$0.30 - -$0.22 | +28.00% | Beat | N/A | 6 | 2 up, 0 down | May 6, 2025 | $20.61M |
| Dec 31, 2024 | -$0.23 | -$0.26 | -$0.33 - -$0.21 | +12.88% | Beat | N/A | 5 | 1 up, 1 down | Feb 27, 2025 | $16.80M |
| Sep 30, 2024 | -$0.64 | -$0.34 | -$0.44 - -$0.25 | -88.24% | Miss | N/A | 6 | 0 up, 0 down | Nov 6, 2024 | $25.71M |
| Jun 30, 2024 | -$0.24 | -$0.38 | -$0.41 - -$0.32 | +36.84% | Beat | N/A | 6 | 0 up, 0 down | Aug 7, 2024 | $22.58M |
| Mar 31, 2024 | -$0.26 | -$0.38 | -$0.52 - -$0.36 | +31.58% | Beat | N/A | 6 | 0 up, 0 down | May 8, 2024 | $19.52M |
| Dec 31, 2023 | -$0.54 | -$0.50 | -$0.63 - -$0.43 | -8.00% | Miss | N/A | 5 | 0 up, 0 down | Feb 28, 2024 | $19.68M |
| Sep 30, 2023 | -$0.48 | -$0.52 | -$0.54 - -$0.52 | +7.69% | Beat | N/A | 5 | 0 up, 1 down | Nov 7, 2023 | $18.25M |
| Jun 30, 2023 | -$0.50 | -$0.54 | -$0.59 - -$0.51 | +7.41% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2023 | $16.70M |
| Mar 31, 2023 | -$0.61 | -$0.58 | -$0.69 - -$0.52 | -5.17% | Miss | N/A | 6 | 0 up, 0 down | May 3, 2023 | $18.86M |
| Dec 31, 2022 | -$0.67 | -$0.64 | -$0.67 - -$0.63 | -4.69% | Miss | N/A | 5 | 0 up, 0 down | Feb 23, 2023 | $16.72M |
| Sep 30, 2022 | -$0.58 | -$0.63 | -$0.68 - -$0.58 | +7.94% | Beat | N/A | 6 | 0 up, 0 down | Nov 2, 2022 | $14.86M |
| Jun 30, 2022 | -$0.60 | -$0.58 | N/A | -3.45% | Miss | N/A | 7 | 0 up, 0 down | Aug 3, 2022 | $18.24M |
| Mar 31, 2022 | -$0.63 | -$0.58 | -$0.63 - -$0.47 | -8.62% | Miss | N/A | 8 | 0 up, 0 down | May 4, 2022 | $15.23M |
| Dec 31, 2021 | -$0.45 | -$0.50 | -$0.53 - -$0.46 | +10.00% | Beat | N/A | 8 | 1 up, 1 down | Feb 24, 2022 | $20.68M |
| Sep 30, 2021 | -$0.40 | -$0.42 | -$0.48 - -$0.38 | +4.76% | Beat | N/A | 8 | 0 up, 0 down | Nov 4, 2021 | $22.26M |
| Jun 30, 2021 | -$0.34 | -$0.39 | -$0.40 - -$0.36 | +12.82% | Beat | N/A | 8 | N/A | Aug 4, 2021 | $21.67M |
| Mar 31, 2021 | -$0.29 | -$0.36 | -$0.39 - -$0.33 | +19.44% | Beat | N/A | 8 | N/A | May 5, 2021 | $20.88M |
| Dec 31, 2020 | -$0.34 | -$0.29 | -$0.38 - -$0.24 | -17.24% | Miss | N/A | 8 | N/A | Feb 25, 2021 | $20.18M |
| Sep 30, 2020 | -$0.27 | -$0.28 | -$0.32 - -$0.23 | +3.57% | Beat | N/A | 8 | N/A | Nov 5, 2020 | $19.82M |
| Jun 30, 2020 | -$0.29 | -$0.34 | -$0.36 - -$0.32 | +14.71% | Beat | N/A | 4 | N/A | Aug 6, 2020 | $19.50M |
| Mar 31, 2020 | -$0.29 | -$0.25 | -$0.32 - -$0.22 | -16.00% | Miss | N/A | 4 | N/A | May 7, 2020 | $19.16M |
| Dec 31, 2019 | -$0.04 | -$0.25 | -$0.31 - -$0.20 | +84.00% | Beat | N/A | 4 | N/A | Mar 25, 2020 | $18.15M |
| Sep 30, 2019 | -$0.17 | -$0.25 | -$0.28 - -$0.21 | +32.00% | Beat | N/A | 4 | N/A | Nov 13, 2019 | $17.15M |
| Jun 30, 2019 | -$0.19 | -$0.26 | -$0.35 - -$0.25 | +26.92% | Beat | N/A | 4 | N/A | Aug 13, 2019 | $15.82M |
| Mar 31, 2019 | -$0.70 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 20, 2019 | $14.07M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.91, after -$1.37 the year before. It was -$1.10 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.91 | N/A |
| Dec 31, 2024 | -$1.37 | N/A |
| Dec 31, 2023 | -$2.13 | N/A |
| Dec 31, 2022 | -$2.48 | N/A |
| Dec 31, 2021 | -$1.48 | N/A |
| Dec 31, 2020 | -$1.19 | N/A |
| Dec 31, 2019 | -$1.10 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,900 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 5,870 | 11 | |
| 2025Q4 | Dec 31, 2025 | 7,573 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,487 | 11 | |
| 2025Q2 | Jun 30, 2025 | 6,553 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,309 | 12 | |
| 2024Q3 | Sep 30, 2024 | 5,538 | 7 | |
| 2024Q2 | Jun 30, 2024 | 5,807 | 10 |
2026Q1 Earnings Call
Opening remarks
Caroline V. Corner Head of Investor Relations Thank you, operator. Welcome to Personalis, Inc.'s first quarter 2026 earnings call. Joining today's call are Christopher M. Hall, Chief Executive Officer; Aaron L. Tachibana, Chief Financial and Chief Operating Officer; and Richard Chen, President and Chief Medical Officer. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of U.S. securities laws, including any statements regarding trends and expectations for our financial performance this year and longer term, cash runway and liquidity position, revenue expectations and timing, size and booking of orders, products, services, technology, expansion of clinical volume, reimbursement goals, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations, market size and our market opportunity, and business outlook. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. We encourage you to review our recent filings, including the risk factors described in our most recent filings. Personalis, Inc. undertakes no obligation to update these statements, except as required by applicable law. Our press release with our first quarter 2026 results is available on our website, www.personalis.com, under the investors section and includes additional details about our financial results. Our website also has our latest SEC filings, which we encourage you to review. A recording of today's call will be available on our website by 5:00 PM Pacific Time today. With that, I would like to turn the call over to Chris.
Christopher M. Hall Chief Executive Officer Good afternoon, everyone. Thank you for joining us. I am incredibly proud of what our team has accomplished in this first quarter, and more importantly, I am energized by where we are going. Since we launched NeXT Personal, we have not just validated our win-in-MRD strategy; we have disrupted the market. Last year in 2025, we established the power of our platform, and this year in 2026, we are scaling it. We are squarely focused on driving volume in this large and rapidly expanding market. Physicians trust NeXT Personal, our clinical test volumes are accelerating, and the broader medical community is validating our roadmap. For those of you new to our story, Personalis, Inc. is changing how cancer recurrence is detected and monitored. We operate at the absolute leading edge of sensitivity for tracking cancer in the blood. Our test requires just a simple blood draw to detect a single fragment of tumor DNA in a background of a million. Let me be clear: this level of ultrasensitivity is no longer just a technical leap forward; it is a clinical necessity. This precision allows oncologists to detect recurrence months and years ahead of standard imaging.
Frequently Asked Questions About PSNL
When is Personalis's next earnings date?
Personalis's next earnings report is expected for Feb 24, 2027.
Did PSNL beat earnings estimates last quarter?
No. Personalis reported EPS of -$0.32 for the quarter ended Sep 30, 2026, below the -$0.25 estimate by 28.00%.
What EPS do analysts expect from PSNL next quarter?
The consensus EPS estimate for Personalis for the quarter ending Dec 31, 2026 is -$0.25 from 9 analysts, with estimates from -$0.31 to -$0.21.
How often does PSNL beat earnings estimates?
Personalis beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +2.59%.
PSNL pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts